抗肿瘤多肽9R-P201诱导下的肝癌HepG2细胞转录组测序分析
发布时间：2018-11-12 19:51
【摘要】：旨在探索多肽9R-P201处理肝癌HepG2细胞后基因融合、单核苷酸多态性(Single nucleotide polymorphism,SNP)突变、可变剪接等事件,并分析差异表达基因所参与的生物学进程与信号通路,以期解析多肽9R-P201在转录组水平对肝癌细胞的调控。通过转录组测序检测9R-P201处理肝癌HepG2细胞前后基因差异表达情况,tophat-fusion软件检测基因融合,SAMTOOLS软件检测SNP位点,r MATS软件鉴定可变剪接,使用基因本体(Gene Ontology,GO)和京都基因与基因组百科全书(Kyoto encyclopedia of genes and genomes,KEGG)富集分析方法对差异表达基因进行功能富集分析。结果共检测到可变剪接事件276个、SNP位点5 557个、基因融合事件45个;同时共得到显著差异表达基因403个,其中上调269个而下调134个,基因的功能富集分析结果显示差异表达基因显著富集细胞生长、迁移等肿瘤相关生物进程,并参与多条与癌症相关的信号通路。研究表明在9R-P201诱导HepG2细胞后,导致表达差异基因显著与肿瘤生物学进程和通路相关,并发生了大量可变剪接、SNP突变、基因融合等事件,这暗示着该多肽有望作为后续肝癌介入治疗潜在药物分子。
[Abstract]:The aim of this study was to explore gene fusion, single nucleotide polymorphism (Single nucleotide polymorphism,SNP) mutation and variable splicing after polypeptide 9R-P201 treatment of HepG2 cells, and to analyze the biological processes and signaling pathways in which differentially expressed genes were involved. The aim of this study was to elucidate the regulation of polypeptide 9R-P201 on hepatoma cells at the transcriptional level. Gene differential expression in HepG2 cells treated with 9R-P201 was detected by transcriptome sequencing, gene fusion was detected by tophat-fusion software, variable splicing was identified by, r MATS software of SNP locus detected by SAMTOOLS software, and gene ontology (Gene Ontology, was used. GO) and Kyoto gene and genome encyclopedia (Kyoto encyclopedia of genes and genomes,KEGG) enrichment analysis method for differentially expressed genes. Results A total of 276 splicing events were detected, including 5 557 SNP loci and 45 gene fusion events. A total of 403 differentially expressed genes were obtained, including 269 up-regulated genes and 134 down-regulated genes. The results of functional enrichment analysis showed that differentially expressed genes significantly enriched cell growth, migration and other tumor-related biological processes. And involved in a number of cancer-related signaling pathways. The results show that after 9R-P201 induces HepG2 cells, the differentially expressed genes are significantly associated with tumor biological processes and pathways, and a large number of events such as variable splicing, SNP mutations, gene fusion, and so on have occurred. This suggests that the polypeptide may be a potential drug molecule for subsequent interventional therapy of liver cancer.
【作者单位】： 西南交通大学生命科学与工程学院;成都市第三人民医院病理科;
【基金】：中央高校基本科研业务费专项资金(2682016YXZT04) 国家大学生创新性实验计划项目(201610613066)
【分类号】：R735.7
，
本文编号：2328052
[Abstract]:The aim of this study was to explore gene fusion, single nucleotide polymorphism (Single nucleotide polymorphism,SNP) mutation and variable splicing after polypeptide 9R-P201 treatment of HepG2 cells, and to analyze the biological processes and signaling pathways in which differentially expressed genes were involved. The aim of this study was to elucidate the regulation of polypeptide 9R-P201 on hepatoma cells at the transcriptional level. Gene differential expression in HepG2 cells treated with 9R-P201 was detected by transcriptome sequencing, gene fusion was detected by tophat-fusion software, variable splicing was identified by, r MATS software of SNP locus detected by SAMTOOLS software, and gene ontology (Gene Ontology, was used. GO) and Kyoto gene and genome encyclopedia (Kyoto encyclopedia of genes and genomes,KEGG) enrichment analysis method for differentially expressed genes. Results A total of 276 splicing events were detected, including 5 557 SNP loci and 45 gene fusion events. A total of 403 differentially expressed genes were obtained, including 269 up-regulated genes and 134 down-regulated genes. The results of functional enrichment analysis showed that differentially expressed genes significantly enriched cell growth, migration and other tumor-related biological processes. And involved in a number of cancer-related signaling pathways. The results show that after 9R-P201 induces HepG2 cells, the differentially expressed genes are significantly associated with tumor biological processes and pathways, and a large number of events such as variable splicing, SNP mutations, gene fusion, and so on have occurred. This suggests that the polypeptide may be a potential drug molecule for subsequent interventional therapy of liver cancer.
【作者单位】： 西南交通大学生命科学与工程学院;成都市第三人民医院病理科;
【基金】：中央高校基本科研业务费专项资金(2682016YXZT04) 国家大学生创新性实验计划项目(201610613066)
【分类号】：R735.7
，
本文编号：2328052
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2328052.html
